|
Originally published In Press as doi:10.1074/jbc.M005490200 on August 10, 2000
J. Biol. Chem., Vol. 275, Issue 41, 32193-32199, October 13, 2000
Stress Pathway Activation Induces Phosphorylation of Retinoid X
Receptor*
Ho-Young
Lee ,
Young-Ah
Suh ,
Megan J.
Robinson§,
John L.
Clifford¶,
Waun K.
Hong ,
James R.
Woodgett**,
Melanie H.
Cobb§,
David J.
Mangelsdorf§ §§, and
Jonathan M.
Kurie ¶¶
From the Department of Thoracic/Head and Neck Medical
Oncology, ¶ Clinical Cancer Prevention, University of Texas
M. D. Anderson Cancer Center, Houston, Texas 77030 , the
§ Department of Pharmacology,
 Howard Hughes Medical Institute, University
of Texas Southwestern Medical Center, Dallas, Texas 75235-9050, and the
** Ontario Cancer Institute, Princess Margaret Hospital, Toronto,
Ontario M4X 1K9, Canada
Received for publication, June 22, 2000, and in revised form, August 3, 2000
 |
ABSTRACT |
Cellular stresses inhibit retinoid signaling, but
the molecular basis for this phenomenon has not been revealed. Here, we present evidence that retinoid X receptor (RXR) is a substrate for both
mitogen-activated protein kinase kinase-4 (MKK4/SEK1) and its
downstream mediator c-Jun N-terminal kinase (JNK). MKK4/SEK1 and JNK
recognized distinct features on RXR in the DE and AB regions, respectively. Phosphorylation by MKK4/SEK1 had profound effects on the
biochemical properties of RXR, inhibiting the expression of genes
activated by RXR-retinoic acid receptor complexes. Tyr-249 in the RXR
DE region was required for the inhibitory effect of MKK4/SEK1. These
effects were significantly reduced in MKK4/SEK1-null cells, indicating
that MKK4/SEK1 is required for the suppression of retinoid signaling by
stress. Findings presented here demonstrate that MKK4/SEK1 can directly
modulate transcription by phosphorylating RXR, a novel MKK4/SEK1 substrate.
 |
INTRODUCTION |
Retinoids are ligands for nuclear hormone receptors, including
retinoid X receptors (RXR , ,
)1 and retinoic acid
receptors (RAR , , ), which are members of the steroid/thyroid
receptor superfamily (1). Of the naturally occurring retinoids,
9-cis retinoic acid is a ligand for RARs and RXRs, and
all-trans-retinoic acid (t-RA) is a ligand for RARs. These
receptors form RXR homodimers and RXR·RAR heterodimers, which
activate gene transcription directly by binding to specific retinoic
acid response elements (RAREs) in gene promoter regions. RXR homodimers
and RXR·RAR heterodimers bind to distinct RAREs, thus activating
different signal transduction pathways. Disruption of genetic loci
associated with specific RARs and RXRs has revealed the importance of
retinoid receptors in mediating the biologic effects of retinoids (2,
3).
Retinoid receptor transcriptional activity is regulated by factors both
intrinsic and extrinsic to the receptor complex. In the unliganded
state, retinoid receptors are bound to co-repressors, including
silencing mediator for retinoid and thyroid hormone receptors and
nuclear receptor co-repressor (4). These co-repressors form complexes
with histone deacetylases to induce chromatin condensation and
transcriptional repression. Ligand binding causes retinoid receptors to
dissociate from co-repressors and bind to co-activators, including
cAMP-responsive element-binding protein-binding protein, p300/CBP-interacting protein, and members of the p160/SRC family of
co-activators, such as steroid receptor co-activator-1 (5). Co-activators form multiprotein complexes that possess intrinsic histone acetyltransferase activity, which is required for retinoid receptor transcriptional activation. Although ligand binding is thought
to be the primary means of activation, retinoid signaling is also
modulated by cellular stresses. For example, ultraviolet (UV)
irradiation decreases intracellular RAR and RXR protein levels
and inhibits ligand-induced transcription of RXR·RAR target genes
(6). Peptide growth factors also decrease retinoid-induced expression
of RXR·RAR target genes and block the biological effects of retinoids
on cells (7, 8). However, the mechanism by which these cellular
stresses inhibit retinoid signaling pathways has not been defined.
Stress-activated signaling pathways include the c-Jun N-terminal
kinases (JNK1-3), also known as stress-activated protein kinases
(SAPKs) (9). These MAP kinases can be activated directly by MAP kinase
kinases such as MKK4/SEK1 and MKK7 (10, 11). Although MAP kinases have
been shown to phosphorylate a number of transcription factors,
including nuclear receptors (12-17), no substrates other than MAP
kinases have been identified for MKKs.
Because stress inhibits retinoid signaling, we tested the hypothesis
that stress-activated protein kinases mediate these effects by acting
on nuclear retinoid receptors. Here we present evidence that RXR is a
substrate of the stress-activated protein kinases JNK and MKK4/SEK1.
MKK4/SEK1 directly phosphorylates RXR, inhibiting ligand-induced
transactivation of RAREs, effects that are greatly diminished in
MKK4/SEK1-null cells. The functional effects of MKK4/SEK1-mediated
phosphorylation support the conclusion that this kinase, thought to be
dedicated to the phosphorylation of stress-sensitive MAP kinases (18,
19), has other substrates that bypass the rest of the downstream MAP
kinase signaling cascade.
 |
EXPERIMENTAL PROCEDURES |
Plasmid Constructs--
This study involved the use of the
following expression plasmids: human GST-tagged constitutively active
MKK4/SEK1 (ST to ED mutant; S287E, T291D) cDNA (MKK4 E-D) (a gift
from Dr. John M. Kyriakis, Harvard University, Boston, MA) (20); human
hemagglutinin-tagged constitutively active MKK1 (R4F mutant) cDNA
(a gift from Dr. Natalie Ahn, University of Colorado, Boulder, CO)
(21); wild type human MKK7 (22); dominant-negative mutants of human
JNK1 and JNK2 cDNAs (a gift from Dr. Bing Su, M.D. Anderson Cancer Center) (23); human skp1 and cul1 (a gift from Dr. J. Wade Harper, Baylor College of Medicine, Houston, TX) (24); human GST-RAR and
GST-TR expression plasmids (gifts from Dr. William W. Lamph, Ligand
Pharmaceuticals, San Diego, CA); luciferase reporter plasmids containing RAREs, which include DR5 (direct repeats of AGGTCA separated
by 5 nucleotides in the context of a heterologous TK promoter), and
RARE (the human RAR- gene promoter from 1470 to +163,
containing a DR5 RARE from position 55 to 35) (25); luciferase
reporter plasmids containing the canonical AP-1 response element
TGAGTCA in the context of a minimal c-fos promoter with no
identifiable regulatory elements except a TATA box (26).
The following human RXR deletion mutants were constructed: AB (amino
acids 1-135), ABC (amino acids 1-200), and DE (amino acids 216-463).
Flag-tagged deletion constructs were created by PCR amplification using
the following primers: B region, sense (5'-GCG AAT TCA GCA GAT GTG CTT
GGT-3'); C region, antisense (5'-CCG AAT TCA GCC CAT GGC CAG GCA-3')
and sense (5'-TAG GTA CCA TGG ACT ACA AGG ACG ACG ACG ACA AGA TCT GCG
CCA TCT GCG GGG ACC GCT CC-3'); E region, antisense (5'-CGG AAT TCT AAG
ACA TTT GGT GCG-3') and sense (5'-CAA GAT CTG GAA CGA GAA TGA GGT GGA
GTC G-3'). Primers used to create His-tagged cDNAs were the
following: A region, sense (5'-GCA GAT CTG GAC ACC AAA CAT TTC-3'); C
region, sense (5'-CAA GAT CTC GCC ATC TGC GGG GA-3'); D region, sense
(5'-AAA GAT CTG AAC GAG AAT GAG GTG-3'). PCR products were subcloned
into pCMX and pET32a (Invitrogen) to create Flag- and His-tagged
cDNAs, respectively. These GST- and His-tagged RXR constructs were
expressed in BL21 cells and purified using glutathione-Sepharose beads
(Amersham Pharmacia Biotech) and nickel column (Qiagen), respectively.
Site-directed mutagenesis was performed on the full-length RXR cDNA
to create Y169F, Y249F, and Y397F mutant cDNAs by PCR amplification
using the following primers: Y169F, sense (5'-GAC CTG ACC TTC ACC TGC
CGC GAC AA-3') and antisense (5'-TTG TCG CGG CAG GTG AAG GTC AGG
TC-3'); Y249F, sense (5'-AAG ACC GAG ACC TTC GTG GAG GCA-3') and
antisense (5'-TGC CTC CAC GAA GGT CTC GGT CTC GGT CTT-3'); Y397F, sense
(5'-TGA GGG AGA AGG TCT TTG CGT CCT T-3') and antisense (5'-AAG GAC GCA
AAG ACC TTC TCC CTC A-3').
Antibodies--
Polyclonal antibodies against histidine repeats,
c-Jun phosphorylated on serine 63, ERK-1 and -2, RAR , RXR , and
JNK1 were purchased (Santa Cruz Biotechnologies). A monoclonal antibody against Flag (M2) was purchased (IBI-Kodak).
Cell Lines--
COS-7 cells, RXR -null F9 cells, RXR -null
F9 cells stably transfected with RXR (Rc7), and mouse embryo
fibroblasts derived from wild type and MKK4/SEK1-null 129/J mice were
maintained in Dulbecco's modified Eagle's medium containing 10%
fetal calf serum (Life Technologies, Inc.), 100 units/ml penicillin,
and 100 units/ml streptomycin in a humidified environment with 5%
CO2. The construction of RXR -null F9 cells and
MKK4/SEK1-null 129/J mice are described elsewhere (27, 28).
Luciferase Assays--
Cells were seeded in 24-well tissue
culture plates and transfected with plasmids using LipofectAMINE (Life
Technologies, Inc.). Total amount of plasmid DNA was adjusted to 1 µg/plate with vector DNA. The transfection solution was removed after
8 h of transfection, and the cells were cultured for 16 h in
medium containing 0.1% serum. Cells were then treated with 1 µM t-RA overnight. When indicated, cells were co-treated
with anisomycin at the indicated dose and time. Cells were subjected to
luciferase assays as described previously (25). Luciferase activities
were expressed as the means and standard deviations from three
identical wells.
Radioactive Labeling of Intact Cells--
Cells were seeded onto
100-mm plates and transfected with plasmid DNAs using LipofectAMINE.
For co-transfections, total transfected plasmid DNA was kept constant
(10 µg) using empty vector. After 8 h of transfection, cells
were serum-starved by changing medium to Dulbecco's modified Eagle's
medium plus 0.1% fetal calf serum. Twenty-four hours after
transfection, cells were treated with t-RA (1 µM) for
16 h and labeled with carrier-free
[32P]orthophosphate or [35S]methionine.
Radioactive labeling was performed in the presence of t-RA (1 µM) to investigate ligand-dependent effects
unless otherwise indicated. 32P-Labeled RXR was
immunoprecipitated with either RXR -specific polyclonal antibody or
Flag-specific monoclonal antibody M2. Immunoprecipitates were washed
four times with lysis buffer, separated by SDS-PAGE, and analyzed by
autoradiography. For subsequent phosphoamino acid analysis, the
phosphopeptides localized by autoradiography were recovered and treated
as described below. Western blotting autoradiographs were quantitated
by scanning densitometry (MultiImage light cabinet, Alpha-Innotech
Corp.).
Protein Kinase Assays--
Following transfection of COS-7 cells
with GST-tagged MKK4 E-D, MKK4/SEK1 was affinity-purified from whole
cell extracts with glutathione-Sepharose beads (Amersham Pharmacia
Biotech) by incubation for 3 h at 4 °C. Activated JNK1 was
immunoprecipated from COS-7 cells transiently co-transfected with MKK4
E-D and JNK1 expression vectors using anti-JNK1 antibodies (Santa Cruz
Biotechnologies). The JNK1 immune complexes were washed twice with
lysis buffer and three times with kinase buffer (25 mM
HEPES (pH 7.4), 25 mM -glycerophosphate, 25 mM MgCl2, 0.5 mM EGTA, 2 mM dithiothreitol, 0.5 mM sodium orthovanadate)
for use in immune complex kinase reactions. Kinase reactions were
performed at 30 °C for 30 min in 30 µl of kinase buffer containing
1 µg of substrate and 10 µCi of [ -32P]ATP.
Kinase reactions were terminated by adding 10 µl of 4× SDS loading
buffer. Samples were boiled and electrophoresed by SDS-PAGE, dried, and
visualized by autoradiography.
Phosphoamino acid analysis was carried out on RXR phosphorylated by
JNK1 and MKK4/SEK1 in vitro and in intact cells. The protein was transferred to polyvinylidene difluoride membrane (Bio-Rad), and
phosphopeptides localized by autoradiography were excised, digested
with 6 N HCl and further dried. Pellets were dissolved in
buffer (pH 1.9) containing 5 µg of unlabeled standard phosphoamino acids, and then separated on 20 × 20-cm thin layer cellulose
plate. The plates were then dried, sprayed with ninhydrin to visualize phosphoamino acid standards, and exposed to x-ray film.
 |
RESULTS |
Activation of Stress Signaling Inhibits the Biologic Effects of
All-trans-retinoic Acid--
We first investigated the effects of
stress on retinoid signaling in cells that are biologically responsive
to retinoid treatment. t-RA induces differentiation of F9
teratocarcinoma cells, a process marked by an increase in the
transcription of several genes mediated directly by RXR·RAR
heterodimeric complexes. Through this mechanism, the expression of
RAR and laminin B1 increases within the first 6 and 48 h,
respectively (29, 30). We examined the effect of stress pathway
activation on RAR and laminin B1 expression. Drugs such as
anisomycin are potent activators of the stress response. Northern
analysis revealed that treatment with anisomycin or transfection with a
constitutively active form of MKK4/SEK1 (MKK4 E-D), an upstream
activator of JNK/SAPKs (31), clearly suppressed t-RA-induced RAR and
laminin B1 mRNA levels (Fig. 1).
Importantly, these effects of stress were not observed in F9 cells that
lack RXR through genetic knockout (Fig. 1). Stably reintroducing
RXR into RXR -null F9 cells (Rc7 cells) restored stress-induced
suppression of t-RA-induced laminin B1 and RAR mRNA (Fig. 1).
These findings demonstrate an absolute requirement of RXR in
mediating stress-induced suppression of retinoid signaling in
vivo.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 1.
Stress inhibits t-RA-induced expression of
the RXR·RAR target genes RAR and laminin B1
in F9 cells, which required the presence of
RXR . Wild type (WT),
RXR -null (RXR / ), or RXR -rescued null F9
(Rc7) cells were treated with or without t-RA
(10 6 M) for 16 h and
subjected to Northern analysis of RAR and laminin B1. Stress
pathways were activated by either treatment with anisomycin (5 µg/ml)
3 h prior to lysis (A) or transient transfection with
constitutively active MKK4/SEK1 (MKK4 E-D) (B).
The total amount of plasmid DNA was adjusted to 10 µg/plate with
vector DNA. The ethidium bromide-stained 28 and 18 S ribosomal RNA
bands are illustrated to show the relative amounts of total RNA loaded
per well.
|
|
Activation of Stress Signaling Inhibits Ligand-induced
Transactivation of RXR·RAR Complexes--
Based on these findings,
we hypothesized that stress inhibits ligand-induced transcriptional
activation of promoters containing RAREs. We investigated retinoid
receptor transcriptional activity in COS-7 cells using reporters
containing RAREs that bind RXR·RAR heterodimeric complexes in the
context of a TK heterologous promoter (DR5) or the RAR- gene
promoter ( -RARE). Treatment of COS-7 cells with anisomycin or
co-transfection with MKK4 E-D markedly inhibited ligand-induced RARE
transcriptional activity, with effects ranging from 50% to 70%
inhibition (Fig. 2). Co-transfection with constitutively active MKK1 (R4F mutant), an activator of ERK MAP kinases, activated an AP-1 response element but did not detectably alter ligand-induced RARE activity (data not shown), suggesting that
transcriptional activity of the RXR·RAR complex is regulated selectively by a stress-sensitive kinase pathway.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 2.
Stress pathway activation inhibits
ligand-induced RARE transcriptional activity. Luciferase assays
were performed on COS-7 cells transiently transfected with reporter
plasmids containing RAREs in the context of a TK heterologous promoter
(DR5) or the RAR- gene promoter ( RARE).
Cells were treated for 16 h with or without t-RA
(10 6 M). To activate stress
pathways, cells were either co-treated with anisomycin at the indicated
concentrations during t-RA treatment or co-transfected with the
indicated amounts of MKK4 E-D. The total amount of plasmid DNA was
adjusted to 1 µg/well with vector DNA. Luciferase results are the
means (± S.D.) of three identical wells.
|
|
Stress-activated Protein Kinases Phosphorylate RXR--
We
investigated whether the transcriptional effects we observed might be
caused by phosphorylation of retinoid receptors. COS-7 cells were
transiently transfected with Flag-RAR or Flag-RXR , treated for
16 h with t-RA (10 6 M), and
labeled with [32P]orthophosphate in the presence or
absence of anisomycin (Fig. 3A). Anisomycin increased the
phosphorylation of RXR but not RAR. RXR phosphorylation was also
enhanced by co-transfection with MKK4 E-D (Fig. 3B). In
these assays, we observed a reduction in the electrophoretic mobility
of RXR, which is consistent with the conclusion that a significant
fraction of RXR was phosphorylated on at least one residue.
Co-transfection of Flag-RXR with other MKKs (MKK7 or MKK1) did not
detectably induce phosphorylation of RXR (Fig. 3C),
demonstrating the specificity of RXR for MKK4/SEK1. Phosphoamino acid
analysis of RXR immunoprecipitated from COS-7 cells radiolabeled with
[32P]orthophosphate following transient co-transfection
with MKK4 E-D and Flag-RXR revealed phosphoserine, phosphothreonine,
and phosphotyrosine (data not shown).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 3.
Stress pathway activation induces
phosphorylation of RXR but not
RAR . COS-7 cells were transiently
transfected with Flag-RXR or Flag-RAR . A,
transfectants were treated with t-RA (10 6
M) for 16 h and then labeled for 3 h with
[32P]orthophosphate in the presence or absence of
anisomycin (5 µg/ml). B and C, cells were
co-transfected with MKK4 E-D, wild type MKK7, or constitutively active
MKK1 (R4F mutant) expression vectors, treated for 16 h with t-RA
(10 6 M), and labeled for 3 h
with [32P]orthophosphate. Cells extracts were subjected
to either immunoprecipitation (IP) with anti-RXR ,
-RAR , or -Flag antibodies or Western analysis (W) with
anti-RXR or -RAR antibodies. MKK7 and MKK1 induced phosphorylation of
JNK and ERK, respectively, in cells labeled with
[32P]orthophosphate (data not shown). The total amount of
plasmid DNA was adjusted to 10 µg/plate with vector DNA. The
different relative densities of upper and lower bands observed in MKK4
E-D-transfected cells (B) by immunoprecipitation with
anti-Flag and anti-RXR antibodies may relate to different affinities of
antibodies for phosphorylated forms of RXR.
|
|
MKK4/SEK1 is an intermediate in a cascade involving an upstream MKK
kinase and MAP kinases (including JNK/SAPK). No MKK4/SEK1 substrates other than MAP kinase family members have been identified. Therefore, we hypothesized that RXR phosphorylation by MKK4/SEK1 is
mediated through JNK/SAPK, which is known to phosphorylate other
steroid receptors (12, 16). We tested the capacity of activated JNK1
and MKK4/SEK1 to phosphorylate RXR in vitro. JNK1 phosphorylated RXR in vitro (Fig.
4A) as well as it did c-Jun (data not shown). The region of RXR phosphorylated by JNK was defined
using RXR deletion mutants. JNK phosphorylated RXR fragments lacking
the DE region but not those lacking the ABC region (Fig. 4A). Phosphoamino acid analysis of the RXR band revealed
phosphoserine and phosphothreonine (Fig. 4B). In the AB
region, there are more than 10 potential JNK phosphorylation sites as
defined by the minimal consensus site (S/TP). Surprisingly, RXR was
also phosphorylated by MKK4 E-D in an in vitro kinase
reaction (Fig. 5A). MKK4 E-D minimally phosphorylated GST-RAR or GST-thyroid receptor (TR) (Fig.
5A), demonstrating the specificity of MKK4/SEK1 for RXR. We
tested the possibility that MKK4/SEK1 bound stably to RXR. COS-7 cells
were co-transfected with plasmids encoding GST-MKK4 E-D and
Flag-RXR . MKK4 E-D was affinity purified from cell lysates and
immunoblotted to RXR antibodies. Stable binding between MKK4 E-D and
RXR was observed (Fig. 5B).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 4.
JNK1 phosphorylates serine and threonine
residues in the AB region of RXR .
A, Activated JNK1 was immunoprecipitated from COS-7 cells
transiently transfected with MKK4 E-D, and immune complex kinase assays
(KA) were performed to examine the effect of activated JNK
on the phosphorylation of His-tagged full-length (RXR) and deletion
mutant RXR, which are illustrated diagrammatically. Samples of
full-length and deletion mutant RXRs were subjected to Western analysis
(W) with anti-histidine antibodies to illustrate their
expression and relative size (designated with arrow).
B, phosphoamino acid analysis of the in vitro
phosphorylated full-length RXR band was performed to examine the effect
of activated JNK on the phosphorylation of serine (pS),
threonine (pT), and tyrosine (pY).
|
|

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 5.
MKK4/SEK1 physically associates with
RXR and phosphorylates serine, threonine, and
tyrosine residues in the RXR DE region.
A, GST-MKK4 E-D was affinity-purified from COS-7 cells
transiently transfected with GST-MKK4 E-D using glutathione-Sepharose
beads, and kinase assays (KA) were performed to examine the
effect of constitutively active MKK4/SEK1 on the phosphorylation of
GST-RXR , -RAR , -TR , and -JNK1 (as a positive control). The
relative size of the bacterial GST fusion proteins is illustrated on a
Coomassie-stained gel. B, COS-7 cells were transiently
co-transfected with Flag-RXR and GST-MKK4 E-D expression vectors,
and GST-MKK4 E-D was affinity-purified with glutathione-Sepharose
beads. Association of MKK4/SEK1 with RXR was examined by subjecting the
GST complex to SDS-PAGE electrophoresis and Western blotting
(W) with anti-RXR antibodies. Cell lysates were subjected
to Western analysis with anti-Flag antibodies to indicate the levels of
RXR expressed in the cells. C, GST-MKK4 E-D was
affinity-purified from COS-7 cells transiently transfected with
GST-MKK4 E-D using glutathione-Sepharose beads, and kinase assays
(KA) were performed to examine the effect of MKK4 E-D on the
phosphorylation of His-tagged full-length (RXR) and deletion mutant
RXR, which are illustrated diagrammatically. Samples of full-length and
deletion mutant RXRs were subjected to Western analysis (W)
with anti-histidine antibodies to illustrate their expression and
relative size (designated with arrow). D, kinase
reactions were subjected to phosphoamino acid analysis to examine the
effect of constitutively active MKK4/SEK1 on the phosphorylation of
serine (pS), threonine (pT), and tyrosine
(pY) in the RXR D-E region (D-E) or full-length
RXR (RXR).
|
|
To determine the region of RXR phosphorylated by MKK4/SEK1, in
vitro kinase assays were performed on RXR deletion mutants. MKK4 E-D phosphorylated a mutant lacking the ABC region of RXR, but not
two RXR mutants lacking the DE region (Fig. 5C).
Phosphoamino acid analysis of the RXR DE region revealed phosphoserine,
phosphothreonine, and phosphotyrosine (Fig. 5D), which is
consistent with the dual-specificity kinase activity of MKK4/SEK1 (10,
31). Tyrosine phosphorylation was more prominent relative to serine in
the context of full-length RXR protein than in the D-E region (Fig.
5D), suggesting that conformational effects influenced
relative rates of phosphorylation of different sites on RXR. This type
of conformational effect has been observed previously for steroid
receptors (32).
Based on the known specificity of MKK4/SEK1 for phosphorylating
tyrosine residues nearby to serine or threonine, we mutated tyrosine
residues with that feature in the D-E region (Tyr-249 and -397) and in
the C (DNA-binding) region (Tyr-169) to identify potential MKK4/SEK1
phosphorylation sites in RXR. Phosphorylation of these RXR mutants by
MKK4 E-D was examined in COS-7 cells labeled with
[32P]orthophosphate and in vitro (Fig.
6A). RXR phosphorylation by MKK4 E-D was reduced by mutation of either tyrosine 397 (Y397F) or 249 (Y249F). Mutation of tyrosine 169 (Y169F) had no effect on RXR
phosphorylation by MKK4 E-D, which is consistent with the result that
the RXR C region was not phosphorylated by MKK4/SEK1. We investigated
the necessity of RXR phosphorylation in the suppression of RARE
transactivation by MKK4/SEK1. Transient co-transfection assays in COS-7
cells revealed that the suppression of RARE activity by MKK4 E-D was
abrogated by mutation of RXR at Tyr-249 (Y249F) but not Tyr-397 (Y397F)
or Tyr-169 (Y169F) (Fig. 6B), indicating that RXR
phosphorylation on Tyr-249 is critical for the effects of MKK4/SEK1 on
RARE transactivation.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 6.
MKK4/SEK1 phosphorylates RXR on tyrosines 248 and 397 in the DE region, and Tyr-248 is required for the suppression
of RARE transactivation by MKK4/SEK1. A, site-directed
mutagenesis was performed on Flag-tagged RXR as illustrated. COS-7
cells were transiently transfected with expression vectors containing
MKK4 E-D and wild type RXR (RXR) or the indicated RXR mutants. The
total amount of plasmid DNA was adjusted to 10 µg/plate with vector
DNA. Cells were then labeled with [32P]orthophosphate or
[35S]methionine (to demonstrate synthesis of the tagged
protein) and subjected to immunoprecipitation (IP) with
anti-Flag antibodies. Immune complex kinase assays (KA) were
performed to examine the effect of MKK4 E-D on His-tagged wild type RXR
(RXR) or the indicated RXR mutants. Aliquots of bacterial RXR were
subjected to Western analysis (W) using anti-RXR antibodies
to demonstrate their relative size. B, COS-7 cells were
transiently co-transfected with 300 ng of a reporter plasmid containing
RAREs in the context of a TK heterologous promoter (DR5) and expression
vectors containing the indicated amounts of MKK4 E-D and 100 ng of wild
type RXR (RXR) or the indicated RXR mutants. Total amount of plasmid
DNA was adjusted to 1 µg per well using empty vector. Cells were
treated for 16 h with or without t-RA
(10 6 M). Luciferase results are
the means (± S.D.) of three identical wells.
|
|
Our findings demonstrate that MKK4/SEK1 phosphorylated RXR domains
distinct from those phosphorylated by JNK1. To confirm that MKK4/SEK1
phosphorylated RXR through a JNK-independent mechanism, COS-7 cells
were co-transfected with MKK4 E-D, a dominant negative JNK construct
(JNK-1 or -2) to block JNK activation, and Flag-RXR . The
transfectants were labeled with [32P]orthophosphate in
the presence of t-RA (10 6 M) and
subjected to immunoprecipitation with anti-Flag antibodies or Western
analysis with anti-phospho-c-Jun antibodies to examine dominant
negative activity of JNK constructs. Dominant negative JNK-1 and -2 suppressed MKK4 E-D-induced phosphorylation of c-Jun but had no
detectable effect on RXR phosphorylation (Fig.
7). Taken together, these findings are
consistent with the conclusion that JNK activation is not required for
RXR phosphorylation by MKK4/SEK1; instead, RXR is a direct substrate of
MKK4/SEK1.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 7.
Dominant negative JNK1 and 2 do not alter RXR
phosphorylation by MKK4/SEK1. COS-7 cells were transiently
co-transfected with Flag-RXR , MKK4 E-D, and dominant negative JNK-1
or -2 (dnJNK). Transfectants were treated for 16 h with
t-RA (10 6 M) and then labeled for
3 h with [32P]orthophosphate. Cells were subjected
to immunoprecipitation (IP) with anti-Flag antibodies to
examine RXR phosphorylation or Western analysis (W) with
anti-phospho-c-Jun antibodies to examine dominant negative activity of
JNK constructs (dominant negative JNK-2 was more effective than
dominant negative JNK1 in inhibiting c-Jun phosphorylation). Relative
to control (Flag-RXR alone), the density of pJun bands from cells
transfected with MKK4 (E-D) alone or co-transfected with MKK4 (E-D) and
dominant negative JNK-1 or -2 were 1.2, 0.88, and 0.57, respectively.
|
|
MKK4/SEK1 Is Required for the Effects of Stress on RXR--
To
determine the physiologic role of MKK4/SEK1 in the suppression of
retinoid signaling by stress, we tested the effect of anisomycin on
wild type and MKK4/SEK1-null mouse embryo fibroblasts. RXR
phosphorylation was examined by immunoprecipitation and Western blot
analysis following [32P]orthophosphate labeling (Fig.
8A). Anisomycin treatment
greatly enhanced RXR phosphorylation in wild type but not
MKK4/SEK1-null cells. Transient transfection assays were performed to
explore the contribution of MKK4/SEK1 to the modulation of
ligand-induced RARE transcriptional activity by anisomycin (Fig.
8B). Anisomycin suppressed t-RA-induced RARE transcriptional
activity in wild type cells, and this effect of anisomycin was
partially lost in MKK4/SEK1-null cells. Transient transfection with
MKK4 E-D was sufficient to restore RXR phosphorylation and to
suppress RARE transcriptional activity in MKK4/SEK1-null cells (Fig. 8,
A and B). Together, these findings support a
physiologic role for MKK4/SEK1 in the suppression of retinoid signaling
by stress.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 8.
MKK4/SEK1 contributes to RXR regulation by
stress. Wild type (+/+) and MKK4/SEK1-null ( / ) mouse embryo
fibroblasts were treated for 16 h with t-RA
(10 6 M). The cells were then
labeled for 3 h with [32P]orthophosphate
(A) in the presence or absence of anisomycin (1 µg/ml).
MKK4/SEK1-null cells were also transiently transfected with
constitutively active MKK4/SEK1 (MKK4 E-D), treated for 16 h with
t-RA (10 6 M), and labeled for
3 h with [32P]orthophosphate. Cells were lysed, and
extracts were subjected to either immunoprecipitation (IP)
or Western analysis (W) with anti-RXR antibodies.
B, stress-induced changes in RARE transcriptional activity
were examined. Wild type and MKK4/SEK1-null cells were transiently
transfected with reporter plasmids containing DR5 RAREs in the context
of a TK heterologous promoter. Transfectants were treated for 16 h
with t-RA (10 6 M) and then with
or without anisomycin (1 µg/ml) for 3 h. MKK4/SEK1-null cells
were also transiently co-transfected with the indicated amounts of MKK4
E-D and treated for 16 h with t-RA (10 6
M). The total amount of plasmid DNA was adjusted to 1 µg/well with vector DNA. Illustrated is the luciferase activity of
cells treated with anisomycin or transfected with MKK4 E-D relative to
that of cells treated with t-RA alone. Results are the means (± S.D.)
of three identical wells.
|
|
 |
DISCUSSION |
Stress signaling is activated in response to a variety of
environmental stimuli, including starvation, changes in osmolarity, heat shock, proinflammatory cytokines, UV light, and DNA damaging agents (33). Potential biologic responses to these stimuli include growth, apoptosis, inflammation, and differentiation. The mechanisms by
which diverse biologic outcomes can result from stress pathway activation have not been elucidated. Toward this end, substrates of
stress-activated protein kinases have been identified, including a
number of nuclear receptors (12-17). Here we provide the first evidence that MKK4/SEK1 can directly modulate transcription by phosphorylating RXR, a novel MKK4/SEK1 substrate. The consequence of
RXR phosphorylation by MKK4/SEK1 is a marked inhibition of retinoid-mediated transcriptional signaling.
Based on the lack of any other known substrates for MKK4/SEK1, it has
been presumed that MKK4/SEK1 acted only upon stress-activated kinases
JNK/SAPKs. However, several lines of evidence presented here indicate
that MKK4/SEK1 can directly phosphorylate RXR in vivo,
independent of its downstream mediator JNK. First, anisomycin enhanced
RXR phosphorylation in wild type but not MKK4/SEK1-null cells,
supporting MKK4/SEK1 as an essential mediator of stress-induced RXR
phosphorylation. Second, MKK4/SEK1 was shown to directly phosphorylate RXR in vitro on serine, threonine, and tyrosine residues,
all of which were phosphorylated in intact cells. Third, MKK4/SEK1 and
JNK phosphorylated distinct RXR domains, indicating that these kinases
recognize different features of RXR. Fourth, neither dominant-negative JNK1 nor JNK2 blocked RXR phosphorylation by MKK4/SEK1 in intact cells,
suggesting that JNK activation was not required. Phosphorylation by
MKK4/SEK1 appears to be specific, since neither MKK7 nor MKK1 phosphorylated RXR, nor did MKK4/SEK1 phosphorylate other nuclear receptors, RAR or TR. These findings demonstrate a new paradigm in MAP
kinase signaling by revealing a novel substrate of MKK4/SEK1, previously believed to act only as an intermediate in a kinase cascade.
Our findings in MKK4/SEK1-null fibroblasts indicate that MKK4/SEK1 is
required for RXR phosphorylation by anisomycin. Further, mutation of
Tyr-249 decreased RXR phosphorylation and abrogated the suppression of
RARE transcriptional activity by MKK4/SEK1. Together, these findings
support a role for RXR phosphorylation by MKK4/SEK1 in stress-induced
inhibition of retinoid signaling. However, suppression of RARE
transcriptional activity by anisomycin was only partially abrogated in
MKK4/SEK1-null cells, suggesting that other anisomycin-sensitive
kinases regulate the activity of RXR·RAR heterodimers. In this study,
MKK7 overexpression had no effect on RXR phosphorylation. As reported
previously (34), we found that JNK1 phosphorylated RXR, but this has
been reported to have no effect on the transactivation properties of
RXR·RAR heterodimers (34). Additional studies will be required to
fully understand the pathways through which stress regulates the
activity of RXR·RAR heterodimers.
What may be the physiologic consequence of stress-mediated inhibition
of RXR function? Chronic exposure of human skin to UV light, a potent
activator of stress pathways, induces tumor formation in
vivo and inhibits the expression of RAR , RXR , and RXR·RAR target genes (6, 35). Retinoid receptors have tumor suppressor properties (36, 37), and loss of specific retinoid receptors is thought
to be an important event in carcinogenesis of the skin, lung, breast,
esophagus, and cervix (38-43). Data presented here offer a potential
mechanism by which environmental stress could suppress retinoid
signaling in epithelial tissues. Supporting a role for RXR
phosphorylation in malignant transformation, RXR is phosphorylated by
MAP kinase in Ras-transformed cells, which results in suppression of
vitamin D receptor:RXR transactivation and attenuation of the growth
inhibitory effects of 1,25-dihydroxyvitamin D3 (44). Future
studies will be required to determine the importance of MKK4/SEK1 as a
physiologic regulator of retinoid signaling and the role of
stress-activated kinases in the pathogenesis of diseases induced by
environmental stress.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grants R29 CA67353, GM56498 (to M. H. C.), and P50 CA70907 (Lung
Cancer SPORE), American Cancer Society Grant RPG-98-189-01-CNE, a grant
from the Robert A. Welch Foundation, and the Howard Hughes Medical
Institute.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
An American Cancer Society Clinical Research Professor.
§§
A Howard Hughes Medical Institute investigator.
¶¶
A Sidney Kimmel Foundation Scholar. To whom
correspondence should be addressed. Tel.: 713-792-6363; Fax:
713-796-8655; E-mail: jmkurie@audumla.mdacc.tmc.edu.
Published, JBC Papers in Press, August 10, 2000, DOI 10.1074/jbc.M005490200
 |
ABBREVIATIONS |
The abbreviations used are:
RXR, retinoid X
receptor;
RAR, retinoic acid receptor;
t-RA, all-trans
retinoic acid;
RARE, retinoic acid response elements;
MAP, mitogen-activated protein;
JNK, Jun N-terminal kinase;
MKK, mitogen-activated protein kinase kinase;
SAPK, stress-activated protein
kinase;
SEK, stress-activated protein/extracellular signal-regulated
kinase kinase;
GST, glutathione S-transferase;
PAGE, polyacrylamide gel electrophoresis;
TK, thymidine kinase;
PCR, polymerase chain reaction;
TR, thyroid receptor.
 |
REFERENCES |
| 1.
|
Mangelsdorf, D. J.,
and Evans, R. M.
(1995)
Cell
83,
835-839
|
| 2.
|
Kastner, P.,
Grondona, J. M.,
Mark, M.,
Gansmuller, A.,
LeMeur, M.,
Decimo, D.,
Vonesch, J. L.,
Dolle, P.,
and Chambon, P.
(1994)
Cell
78,
987-1003
|
| 3.
|
Lohnes, D.,
Kastner, P.,
Dierich, A.,
Mark, M.,
LeMeur, M.,
and Chambon, P.
(1993)
Cell
73,
643-658
|
| 4.
|
Nagy, L.,
Kao, H. Y.,
Chakravarti, D.,
Lin, R. J.,
Hassig, C. A.,
Ayer, D. E.,
Schreiber, S. L.,
and Evans, R. M.
(1997)
Cell
89,
373-380
|
| 5.
|
McKenna, N. J.,
Xu, J.,
Nawaz, Z.,
Tsai, S. Y.,
Tsai, M. J.,
and O'Malley, B. W.
(1999)
J. Steroid Biochem. Mol. Biol.
69,
3-12
|
| 6.
|
Wang, Z.,
Boudjelal, M.,
Kang, S.,
Voorhees, J. J.,
and Fisher, G. J.
(1999)
Nature Med.
5,
418-422
|
| 7.
|
Miller, L. A.,
Cheng, L. Z.,
and Wu, R.
(1993)
Cancer Res.
53,
2527-2533
|
| 8.
|
Andreatta-Van Leyen, S.,
Hembree, J. R.,
and Eckert, R. L.
(1994)
J. Cell. Physiol.
160,
265-274
|
| 9.
|
Schaeffer, H. J.,
and Weber, M. J.
(1999)
Mol. Cell. Biol.
19,
2435-2444
|
| 10.
|
Lin, A.,
Minden, A.,
Martinetto, H.,
Claret, F. X.,
Lange-Carter, C.,
Mercurio, F.,
Johnson, G. L.,
and Karin, M.
(1995)
Science
268,
286-290
|
| 11.
|
Swantek, J. L.,
Christerson, L.,
and Cobb, M. H.
(1999)
J. Biol. Chem.
274,
1167-1171
|
| 12.
|
Camp, H. S.,
Tafuri, S. R,
and Leff, T.
(1999)
Endocrinology
140,
392-397
|
| 13.
|
Hammer, G. D.,
Krylova, I.,
Zhang, Y.,
Darimont, B. D.,
Simpson, K.,
Weigel, N. L.,
and Ingraham, H. A.
(1999)
Mol. Cell.
3,
521-526
|
| 14.
|
Hu, E.,
Kim, J. B.,
Sarraf, P.,
and Spiegelman, B. M.
(1996)
Science
274,
2100-2103
|
| 15.
|
Kato, S.,
Endoh, H.,
Masuhiro, Y.,
Kitamoto, T.,
Uchiyama, S.,
Sasaki, H.,
Masushige, S.,
Gotoh, Y.,
Nishida, E.,
Kawashima, H.,
Metzger, D.,
and Chambon, P.
(1995)
Science
270,
1491-1494
|
| 16.
|
Rogatsky, I.,
Logan, S. K.,
and Garabedian, M. J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
2050-2055
|
| 17.
|
Tremblay, A.,
Tremblay, G. B.,
Labrie, F.,
and Giguere, V.
(1999)
Mol. Cell.
3,
513-519
|
| 18.
|
Lewis, T. S.,
Shapiro, P. S.,
and Ahn, N. G.
(1998)
Adv. Cancer Res.
74,
49-139
|
| 19.
|
Cobb, M. H.
(1999)
Prog. Biophys. Mol. Biol.
71,
479-500
|
| 20.
|
Zanke, B. W.,
Boudreau, K.,
Rubie, E.,
Winnett, E.,
Tibbles, L. A.,
Zon, L.,
Kyriakis, J.,
Liu, F. F.,
and Woodgett, J. R.
(1996)
Curr. Biol.
6,
606-613
|
| 21.
|
Mansour, S. J.,
Matten, W. T.,
Hermann, A. S.,
Candia, J. M.,
Rong, S.,
Fukasawa, K.,
Vande Woude, G. F.,
and Ahn, N. G.
(1994)
Science
265,
966-970
|
| 22.
|
Tournier, C.,
Whitmarsh, A. J.,
Cavanagh, J.,
Barrett, T.,
and Davis, R. J.
(1999)
Mol. Cell. Biol.
19,
1569-1581
|
| 23.
|
Liu, Z. G.,
Hsu, H.,
Goeddel, D. V.,
and Karin, M.
(1996)
Cell
87,
565-576
|
| 24.
|
Winston, J. T.,
Strack, P.,
Beer-Romero, P.,
Chu, C. Y.,
Elledge, S. J.,
and Harper, J. W.
(1999)
Genes Dev.
13,
270-283
|
| 25.
|
Kim, Y. H.,
Dohi, D. F.,
Han, G. R.,
Zou, C. P.,
Oridate, N.,
Walsh, G. L.,
Nesbitt, J. C.,
Xu, X. C.,
Hong, W. K.,
Lotan, R.,
and Kurie, J.
(1995)
Cancer Res.
55,
5603-5610
|
| 26.
|
Lee, H. Y.,
Dawson, M. I.,
Walsh, G. L.,
Nesbitt, J. C.,
Eckert, R. L.,
Fuchs, E.,
Hong, W. K.,
Lotan, R.,
and Kurie, J. M.
(1996)
Cell Growth Differ.
7,
997-1004
|
| 27.
|
Clifford, J.,
Chiba, H.,
Sobieszczuk, D.,
Metzger, D.,
and Chambon, P.
(1996)
EMBO J.
15,
4142-4155
|
| 28.
|
Nishina, H.,
Fischer, K. D.,
Radvanyi, L.,
Shahinian, A.,
Hakem, R.,
Rubie, E. A.,
Bernstrin, A.,
Mak, T. W.,
Woodgett, J. R.,
and Penninger, J. M.
(1997)
Nature
385,
350-353
|
| 29.
|
Hu, L.,
and Gudas, L. J.
(1990)
Mol. Cell. Biol.
10,
391-396
|
| 30.
|
Vasios, G. W.,
Gold, J. D.,
Petkovich, M.,
Chambon, P.,
and Gudas, L. J.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
9099-9103
|
| 31.
|
Sanchez, I.,
Hughes, R. T.,
Mayer, B. J.,
Yee, K.,
Woodgett, J. R.,
Avruch, J.,
Kyriakis, J. M.,
and Zon, L. I.
(1994)
Nature
372,
794-798
|
| 32.
|
Hilliard, G. M.,
Cook, R. G.,
Weigel, N. L.,
and Pike, J. W.
(1994)
Biochem.
33,
4300-4311
|
| 33.
|
Woodgett, J. R.,
Avruch, J.,
and Kyriakis, J.
(1996)
Cancer Surv.
27,
127-138
|
| 34.
|
Adam-Stitah, S.,
Penna, L.,
Chambon, P.,
and Rochette-Egly, C.
(1999)
J. Biol. Chem.
274,
18932-18941
|
| 35.
| Kyriakis, J. M. & Avruch, J. J. Biol. Chem.
271, 24313-24316
|
| 36.
|
Shea, C. R.,
and Parrish, J. A.
(1991)
in
Physiology, Biochemistry & Molecular Biology of the Skin
(Goldsmith, L. A., ed), Vol. II
, pp. 910-927, Oxford Univeristy Press, New York
|
| 37.
|
Berard, J.,
Laboune, F.,
Mukuna, M.,
Masse, S.,
Kothary, R.,
and Bradley, W. E.
(1996)
FASEB J.
10,
1091-1097
|
| 38.
|
Houle, B.,
Rochette-Egly, C.,
and Bradley, W. E. C.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
985-989
|
| 39.
|
Geisen, C.,
Denk, C.,
Gremm, B.,
Baust, C.,
Karger, A.,
Bollag, W.,
and Schwarz, E.
(1997)
Cancer Res.
57,
1460-1467
|
| 40.
|
Lotan, R.,
Xu, X. C.,
Lippman, S. M.,
Ro, J. Y.,
Lee, J. S.,
Lee, J. J.,
and Hong, W. K.
(1995)
N. Engl. J. Med.
332,
1405-1410
|
| 41.
|
Xu, X. C.,
Liu, E.,
Tahara,
Lippman, S. M.,
and Lotan, R.
(1999)
Cancer Res.
59,
2477-2483
|
| 42.
|
Xu, X. C.,
Sneige, N.,
Liu, X.,
Nandagiri, R.,
Lee, J. J.,
Lukmanji, F.,
Hortobagyi, G.,
Lippman, S. M.,
Dhingra, K.,
and Lotan, R.
(1997)
Cancer Res.
57,
4992-4996
|
| 43.
|
Xu, X. C.,
Sozzi, G.,
Lee, J. S.,
Lee, J. J.,
Pastorino, U,
Pilotti, S.,
Kurie, J. M.,
Hong, W. K.,
and Lotan, R.
(1997)
J. Natl. Cancer Inst.
89,
624-629
|
| 44.
|
Solomon, C.,
White, J. H.,
and Kremer, R.
(1999)
J. Clin. Invest.
103,
1729-1735
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Sun, V. Montana, K. Chellappa, Y. Brelivet, D. Moras, Y. Maeda, V. Parpura, B. M. Paschal, and F. M. Sladek
Phosphorylation of a Conserved Serine in the Deoxyribonucleic Acid Binding Domain of Nuclear Receptors Alters Intracellular Localization
Mol. Endocrinol.,
June 1, 2007;
21(6):
1297 - 1311.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q.-P. Li, X. Qi, R. Pramanik, N. M. Pohl, M. Loesch, and G. Chen
Stress-induced c-Jun-dependent Vitamin D Receptor (VDR) Activation Dissects the Non-classical VDR Pathway from the Classical VDR Activity
J. Biol. Chem.,
January 19, 2007;
282(3):
1544 - 1551.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Liu, J.-f. Wu, Y.-y. Zhan, H.-z. Chen, X.-y. Zhang, and Q. Wu
Regulation of the Orphan Receptor TR3 Nuclear Functions by c-Jun N Terminal Kinase Phosphorylation
Endocrinology,
January 1, 2007;
148(1):
34 - 44.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Bogoyevitch and B. Kobe
Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal Kinases
Microbiol. Mol. Biol. Rev.,
December 1, 2006;
70(4):
1061 - 1095.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. L. Zimmerman, S. Thevananther, R. Ghose, A. R. Burns, and S. J. Karpen
Nuclear Export of Retinoid X Receptor {alpha} in Response to Interleukin-1beta-mediated Cell Signaling: ROLES FOR JNK AND SER260
J. Biol. Chem.,
June 2, 2006;
281(22):
15434 - 15440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Jahan and J. Y. L. Chiang
Cytokine regulation of human sterol 12{alpha}-hydroxylase (CYP8B1) gene
Am J Physiol Gastrointest Liver Physiol,
April 1, 2005;
288(4):
G685 - G695.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Srinivas, D. M. Juroske, S. Kalyankrishna, D. D. Cody, R. E. Price, X.-C. Xu, R. Narayanan, N. L. Weigel, and J. M. Kurie
c-Jun N-Terminal Kinase Contributes to Aberrant Retinoid Signaling in Lung Cancer Cells by Phosphorylating and Inducing Proteasomal Degradation of Retinoic Acid Receptor {alpha}
Mol. Cell. Biol.,
February 1, 2005;
25(3):
1054 - 1069.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|